Chi­nook paus­es PhI kid­ney dis­ease tri­al af­ter se­ri­ous ad­verse event

Chi­nook Ther­a­peu­tics said it tem­porar­i­ly halt­ed dos­ing par­tic­i­pants in the Phase I tri­al of its treat­ment for an ul­tra-rare ge­net­ic kid­ney dis­ease af­ter one of the vol­un­teers had a se­ri­ous ad­verse event.

The ad­verse event hap­pened af­ter the per­son’s first dose of the drug, an oral LD­HA in­hibitor. The Phase I tri­al is meant to sign up about 100 peo­ple, and the vol­un­teer with the side ef­fect re­ceived a 125mg dose.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER